

# Cornelis Smit

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3045498/publications.pdf>

Version: 2024-02-01

16  
papers

378  
citations

932766

10  
h-index

940134

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 275-285.	1.5	135
2	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 659-669.	1.6	50
3	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 303-317.	1.1	37
4	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 978-985.	1.3	23
5	Efficient Synthesis and Applications of Peptides containing Adenylylated Tyrosine Residues. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 9200-9204.	7.2	21
6	Implications for IV posaconazole dosing in the era of obesity. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1006-1013.	1.3	18
7	Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. <i>Clinical Infectious Diseases</i> , 2020, 70, 2213-2215.	2.9	16
8	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 112.	1.7	13
9	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years. <i>AAPS Journal</i> , 2021, 23, 53.	2.2	12
10	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1333-1343.	1.6	11
11	Optimizing moxidectin dosing for <i>Strongyloides stercoralis</i> infections: Insights from pharmacometric modeling. <i>Clinical and Translational Science</i> , 2022, 15, 700-708.	1.5	10
12	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3286-3292.	1.3	9
13	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1167-1175.	1.6	9
14	Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with <i>Strongyloides Stercoralis</i> : Support for a Fixed-Dose Treatment Regimen. <i>Clinical Pharmacokinetics</i> , 2022, 61, 123-132.	1.6	7
15	Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates. <i>Archives of Disease in Childhood</i> , 2021, , archdischild-2020-321381.	1.0	4
16	Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 561-567.	0.6	3